Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol augmentation of exposure therapy for treatment-refractory phobic disorders
2014-004094-17Phase 3Active
- Sponsor
- Utrecht University
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Social Anxiety Disorder (SAD), Agoraphobia with panic disorder (PD/A) and specific phobia comparing Cannabidiol + exposure therapy with Placebo + exposure therapy (2 arms). Primary endpoint: Fear Questionnaire. Started Sep 2015; status: active.
02
Drugs
cannabidiol
03
Conditions
Social Anxiety Disorder (SAD)Agoraphobia with panic disorder (PD/A)specific phobia
Beyond the preview
Go deeper on 2014-004094-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004094-17.